{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Survey Questionnaire
  1. On an average, how many newly diagnosed Neuroendocrine Tumour (NET) patients do you see every year? *
  2. Of all the NET patients you see, what % of patients are having__ *
    3. Non-metastatic disease
    %
    Metastatic disease
    %
  3. In your clinical practice, what % of metastatic NET are eligible for upfront surgery ? *
    4. %
  4. Please mention the % bifurcation of all the NET patients presented to you, *
    5. Gastro Entero Pancreatic NET
    %
    Lung/Thymus NET
    %
    Other NET
    %
    Patients with unknown primary origin
    %
  5. Among all patients diagnosed with GEP NET, please mention the bifurcation according to their functional status. *
    6. Non-functional NET
    %
    Functional NET
    %
  6. Please mention the % wise split of NET patients according to tumour differentiation_ *
    7. Well differentiated tumour
    %
    Poorly differentiated tumour
    %
  7. Please mention the % wise split of NET patients according to tumour grade_ *
    8. Grade 1/2
    %
    Grade 3
    %
  8. Among all the NET patients screened for somatostatin receptor (SSTR) scan, what % of patients are reported SSTRs positive? *
    9. %
  9. Among all non-functional NET patients, what % of patients receive systemic therapy vs observation? *
    10. Observation
    %
    Systemic Treatment
    %
  10. What is your opinion on the usage of Somatostatin Analogues (SSA) in SSTRs positive NET? *

  11. Please mention the duration of treatment for Octreotide depot while using in 1st line management of metastatic NET patients. *
    12. Months
  12. Of all the patients prescribed with Octreotide depot, mention the % split of recommended doses in your practice: *
    13. 20MG OD Every 4 Week
    %
    30MG OD Every 4 Week
    %
    30MG OD Every 3 Week
    %
    40MG OD Every 4 Week
    %
    60MG OD Every 4 Week
    %
    %
  13. What is your opinion if a higher strength Octreotide LAR depot formulation, such as 60 mg/90mg (every 12 weeks), is made available for use? *

  14. What % of your SSTR positive NET patients taking Octreotide treatment require dose escalation for symptom control? *
    15. %
  15. Please mention % wise usage of various therapies for refractory carcinoid syndrome NET patients (without evidence of radiological progression)*
    16. Escalated dose of octreotide depot
    %
    Everolimus
    %
    PRRT + Octreotide Depot
    %
    Sunitinib
    %
    CAPTEM
    %
    %
  16. Please mention % wise usage of various therapies for refractory NET patients with evidence of radiological progression*
    17. Everolimus
    %
    Octreotide Depot + Eveolimus
    %
    PRRT + Octreotide Depot
    %
    Sunitinib
    %
    CAPTEM
    %
    %